MAP2K7 and non-small cell lung carcinoma: We previously found that autophagy activation compensates for the loss of Lkb1 in Kras-driven lung tumorigenesis [5], which prompted us to preclinically evaluate the potential of using autophagy inhibition together with FDA-approved MEK/ERK inhibitors for the treatment of KL NSCLC.